2.95
+0.04(+1.37%)
Currency In USD
| Previous Close | 2.91 |
| Open | 2.9 |
| Day High | 2.95 |
| Day Low | 2.84 |
| 52-Week High | 6.01 |
| 52-Week Low | 1.1 |
| Volume | 219,173 |
| Average Volume | 347,561 |
| Market Cap | 58M |
| PE | -1.33 |
| EPS | -2.21 |
| Moving Average 50 Days | 2.76 |
| Moving Average 200 Days | 2.62 |
| Change | 0.04 |
If you invested $1000 in NRx Pharmaceuticals, Inc. (NRXP) since IPO date, it would be worth $30.73 as of September 29, 2025 at a share price of $2.95. Whereas If you bought $1000 worth of NRx Pharmaceuticals, Inc. (NRXP) shares 5 years ago, it would be worth $0.03 as of September 29, 2025 at a share price of $2.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx’s Proposed Strength of Preservative-Free Ketamine
GlobeNewswire Inc.
Sep 24, 2025 12:03 PM GMT
Suitability Petition is required for shift from multidose packaging of ketamine to single-patient dose preservative free ketamineGranting of Suitability Petition enables re-filing of Abbreviated New Drug Application (ANDA) for NRx’s patent-pending pr
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics
GlobeNewswire Inc.
Sep 08, 2025 12:17 PM GMT
Dura Medical, together with pending acquisitions of Neurospa TMS and Cohen & Associates, to provide contiguous coverage at more than 8 locations along Florida’s West Coast, with planned coverage throughout the Florida PeninsulaDura delivers a full ra
NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th
GlobeNewswire Inc.
Sep 03, 2025 12:03 PM GMT
WILMINGTON, Del., Sept. 03, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), an interve